Anju Singh joined the NCATS Division of Preclinical Innovation in 2012 as a research scientist in biomolecular screening and probe development. She received a Ph.D. in immunology at the University of Wisconsin–Madison, where she worked under M. Suresh, D.V.M., M.V.Sc., Ph.D., on regulating memory CD8 T-cell differentiation during viral infections. As a postdoctoral fellow in the laboratory of Laurie Glimcher, M.D., at Harvard University, Singh studied anabolic regulators of bone mass and stem cell biology of the skeletal system.
Singh is interested in the use of small molecules for immunomodulation. Her research interests include:
- Regulating helper T-cell differentiation and plasticity, especially in characterizing potential therapeutic compounds that inhibit pathogenic Th17 cells and suppress autoimmunity.
- Developing immune activators to increase cytotoxic T-cell function, particularly during cancers, immunodeficiencies and infectious diseases.
- Developing in vitro disease models using induced pluripotent stem cells derived from patients and multiple cell-type models for diseases affecting multiple systems.
- Osteoimmunology, an emerging field that focuses on understanding the complex interactions between the immune and skeletal systems and on developing novel therapies for diseases affecting both systems.
Singh has extensive experience in implementing high-throughput screens and using many assay technologies, from cell-based reporter gene assays and multiplex gene expression assays to flow cytometry. She also has knowledge and expertise in in vivo animal models and in high-throughput screening using primary cells.